June 29, 2026 · Form 4 insider transaction
Booth Bruce sold 10,658 shares of Kymera Therapeutics, Inc. at $108.28 per share, a transaction worth $1.15M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025.; The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6).; These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any.